PreprintArticleVersion 1This version is not peer-reviewed
Combating Candida glabrata: Screening 5,6-Dihydrotetrazolo[1,5-c]Quinazolines through In Vitro Studies, Molecular Docking, QSAR and Toxicity Assessments
Antypenko, L.; Antypenko, O.; Fominichenko, A.; Karnaukh, I.; Kovalenko, S.; Arisawa, M. Combating Candida glabrata: Screening 5,6-Dihydrotetrazolo[1,5-c]Quinazolines through In Vitro Studies, Molecular Docking, QSAR and Toxicity Assessments. Preprints2024, 2024102009. https://doi.org/10.20944/preprints202410.2009.v1
APA Style
Antypenko, L., Antypenko, O., Fominichenko, A., Karnaukh, I., Kovalenko, S., & Arisawa, M. (2024). Combating <i>Candida glabrata</i>: Screening 5,6-Dihydrotetrazolo[1,5-<i>c</i>]Quinazolines through <i>In Vitro</i> Studies, Molecular Docking, QSAR and Toxicity Assessments. Preprints. https://doi.org/10.20944/preprints202410.2009.v1
Chicago/Turabian Style
Antypenko, L., Sergiy Kovalenko and Mieko Arisawa. 2024 "Combating <i>Candida glabrata</i>: Screening 5,6-Dihydrotetrazolo[1,5-<i>c</i>]Quinazolines through <i>In Vitro</i> Studies, Molecular Docking, QSAR and Toxicity Assessments" Preprints. https://doi.org/10.20944/preprints202410.2009.v1
Abstract
Candida glabrata (Nakaseomyces glabratus), the second most prevalent Candida pathogen globally, has emerged as a major clinical threat due to its ability to develop high-level azole resistance. In this study, two new 5,6-dihydrotetrazolo[1,5-c]quinazoline derivatives (c11 and c12) were synthesized and characterized using IR, LC-MS, 1Н and 13C NMR spectra. Along with 13 previously reported analogues, these compounds underwent in vitro antifungal testing against clinical C. glabrata isolates using a serial dilution method (0.125-64 mg/L). Remarkably, compounds c5 and c1 exhibited potent antifungal activity, with minimum inhibitory concentrations of 0.37 μM and 0.47 μM, respectively – about 20-fold improvement over standard drugs like amphotericin B, caspofungin, and micafungin. A detailed structure-activity relationship analysis revealed crucial molecular features enhancing antifungal potency. Extensive molecular docking studies across 18 protein targets explored potential binding pockets and affinities of the lead compounds. A robust 3D-QSAR model, incorporating molecular descriptors Mor26m and Mor29e, displayed good predictive ability for antifungal activity. In silico predictions indicated an absence of herbicidal effect, negligible environmental toxicity (to honeybees, avian species, and aquatic organisms), and mild human toxicity concerns for these compounds. This comprehensive approach aims to develop novel and effective antifungal compounds against the clinically relevant pathogen C. glabrata.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
